Crossbow Therapeutics Funding: $80M Raised, Series A (2023)
Crossbow Therapeutics is a Biotech company based in Cambridge. It has raised $80M in total funding. Latest round: Series A.
Crossbow Therapeutics funding overview
Crossbow Therapeutics is a Biotech company based in Cambridge. Crossbow Therapeutics has raised $80M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in July 2023. The round record for Crossbow Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include MPM BioImpact, Pfizer Ventures. 2 distinct backers are named across the disclosed rounds.
Crossbow Therapeutics at a glance
Total raised
$80M
Latest round
Series A
Latest round date
July 2023
Industry
Biotech
Headquarters
Cambridge
Notable investors
MPM BioImpact, Pfizer Ventures
Frequently asked about Crossbow Therapeutics funding
How much has Crossbow Therapeutics raised?
Crossbow Therapeutics has raised $80M in total disclosed funding across the rounds on record.
Who has invested in Crossbow Therapeutics?
MPM BioImpact, Pfizer Ventures are named among the investors backing Crossbow Therapeutics.
What was the latest Crossbow Therapeutics funding round?
The most recent disclosed round is a Series A, announced in July 2023.
Where is Crossbow Therapeutics based?
Crossbow Therapeutics is based in Cambridge.
What sector does Crossbow Therapeutics operate in?
Crossbow Therapeutics is tracked under Biotech from Cambridge, with $80M in disclosed funding.
When did Crossbow Therapeutics last raise?
The last disclosed Crossbow Therapeutics round closed in July 2023 at Series A.
Crossbow Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in Cambridge below to benchmark round size and investor mix.
